Mentari Therapeutics Presents Migraine Drug Pipeline, Targets First Clinical Data in 2027

LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • Mentari Therapeutics targets a first-quarter 2027 regulatory filing for migraine candidate MT-002, with Phase 1 data expected by year-end. * MT-001 Phase 1 data are expected in mid-2027, followed by initial Phase 2 proof-of-concept data in migraine patients in 2028. * The five-program antibody pipeline includes MT-002, which targets both PACAP and CGRP to potentially improve migraine prevention. * About $490 million raised to date supports development beyond key anticipated milestones. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mentari Therapeutics Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.